Reuters logo
BRIEF-Calithera Biosciences expands clinical collaboration with Bristol-Myers Squibb
November 7, 2017 / 1:38 PM / 15 days ago

BRIEF-Calithera Biosciences expands clinical collaboration with Bristol-Myers Squibb

Nov 7 (Reuters) - Calithera Biosciences Inc

* Initial results from Phase 2 study of CB-839 in combination with opdivo® (nivolumab) to be presented at the Society for Immunotherapy of Cancer Meeting

* Calithera Biosciences Inc - ‍expanding Bristol-Myers Squibb clinical collaboration​

* Calithera Biosciences Inc - ‍expanded its existing clinical collaboration with Bristol-Myers Squibb, evaluating CB-839 in combination with opdivo​

* Calithera Biosciences Inc - ‍analysis of all safety evaluable patients demonstrated CB-839 was well tolerated when combined with opdivo​

* Calithera Biosciences - ‍among 16 evaluable melanoma patients, one patient achieved a complete response and two patients achieved partial responses​

* Calithera Biosciences Inc - ‍study will be expanded to enroll additional melanoma patients​

* Calithera Biosciences Inc - ‍as part of expanded collaboration, melanoma development costs will be shared​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below